TIDMOPTI

RNS Number : 3061K

OptiBiotix Health PLC

01 September 2021

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

PDMR Dealing

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                               www.optibiotix.com 
 Neil Davidson, Chairman                           Contact via Walbrook 
                                                                  below 
 Stephen O'Hara, Chief Executive 
 
 Cairn Financial Advisers LLP (NOMAD)                Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                      Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                     Mob: 07876 741 001 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1      Details of the person discharging managerial responsibilities/person 
         closely associated 
       ------------------------------------------------------------------------------------------ 
 a.     Name                                      René Kamminga 
       ----------------------------------------  ------------------------------------------------ 
 2      Reason for notification 
       ----------------------------------------  ------------------------------------------------ 
 a.     Position/Status                           PDMR 
       ----------------------------------------  ------------------------------------------------ 
 b.     Initial notification/                     Initial Notification 
         Amendment 
       ----------------------------------------  ------------------------------------------------ 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ------------------------------------------------------------------------------------------ 
 a.     Name                                      OptiBiotix Health Plc 
       ----------------------------------------  ------------------------------------------------ 
 b.     LEI                                       213800UKYQFT941QHS14 
       ----------------------------------------  ------------------------------------------------ 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions have 
         been conducted 
       ------------------------------------------------------------------------------------------ 
 a.     Description of                            8,188 ordinary shares of 2p each 
         the financial 
         instrument, type 
         of instrument                             ISIN: GB00BP0RTP38 
 
         Identification 
         Code 
       ----------------------------------------  ------------------------------------------------ 
 b.     Nature of the                             Purchase of 8,188 ordinary shares in the 
         transaction                               Company 
       ----------------------------------------  ------------------------------------------------ 
 
 c.     Price(s) and volume(s)                     Price(s) per               Volume(s) 
                                                    share 
       ----------------------------------------   ------------------------- 
                                                   55.4p                      8,188 
                                                  -------------------------  ---------------- 
 
 d.          Aggregated information 
               *    Volume                          n/a 
 
 
               *    Price 
       ----------------------------------------  ------------------------------------------------ 
 e.     Date of the transaction                   31 August 2021 
       ----------------------------------------  ------------------------------------------------ 
 f.     Place of the transaction                  London Stock Exchange, AIM 
       ----------------------------------------  ------------------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSDUEFFEFSESA

(END) Dow Jones Newswires

September 01, 2021 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Optibiotix Health Charts.